Fubon Financial Holding Co (富邦金控) yesterday said that its insurance unit would weather rising COVID-19 insurance claims and no fundraising is needed.
Fubon Insurance Co (富邦產險) said it has sold about 2.31 million COVID-19 insurance policies and as of the middle of this month had paid NT$1.1 billion (US$37.09 million) of claims from 29,000 policyholders.
It pays a total of NT$50 million per day in claims, it said.
It is difficult to calculate how much more compensation it would have to pay, as local COVID-19 infections are still on the rise, with a peak not expected until next month, Fubon Insurance said.
Fubon Insurance reiterated that it would not avoid its responsibility to policyholders.
“Fubon Insurance has net value of NT$30 billion to NT$40 billion, and assets of NT$130 billion, not to mention the high net value of Fubon Financial,” Fubon Financial president Jerry Harn (韓蔚廷) told an investors’ conference amid speculation that the company would be unable to bear the burden.
Policyholders would receive compensation, Harn said.
The loss rate on COVID-19 insurance policies was about 15 percent, the company said.
Three factors would affect the figure, including the ultimate number of local infections, the government’s virus policy and clarification of disputes, it said.
If the financial pressure becomes too heavy, Fubon Insurance would consider applying to the Financial Supervisory Commission (FSC) to use part of its special reserve to write off losses, it said.
The insurer can allocate as much as NT$15.5 billion, it said.
Fubon Financial Holding reported an annual decline of 9.4 percent in net profit to NT$46.5 billion for the first quarter, mainly because of a drop of 7 percent in net profit at Fubon Life Insurance Co (富邦人壽) to NT$36.4 billion amid decreasing first-year premiums and lower returns on investments, corporate data showed.
Realized capital gains from fixed-income investments plunged about 75 percent year-on-year to NT$6.7 billion in the first quarter, the data showed.
In related news, China Life Insurance Co (中國人壽) yesterday announced that even though its insurance terms do not stipulate that it must compensate policyholders who catch COVID-19, but are not hospitalized due to the virus, it would pay those who stay home as much as it pays for hospitalizations, as long as they are prescribed drugs.
The drugs are not limited to oral antivirus drugs such as Paxlovid and molnupiravir, or a traditional Chinese compound called Taiwan Chingguan Yihau (清冠一號), or NRICM101, but policyholders should provide prescriptions, a doctor’s diagnosis and a digital COVID-19 certificate with their claims, China Life said.
The FSC has said that insurance firms can decide themselves — while adhering to the terms of their policies — whether to compensate people who catch COVID-19, but are not hospitalized.
STEADY: Prices are to rebound following inventory rebuilding demand, TrendForce said, with Samsung Electronics Co further trimming capacity as it slashes DDR4 lines The contract prices of DRAM chips are to rise by as much as 18 percent sequentially this quarter — the first price upticks in about eight quarters — driven mainly by inventory rebuilding demand for DRAM chips used in mobile devices and PCs, TrendForce Corp (集邦科技) projected yesterday. The price rebound is led by a quarterly increase of mobile DRAM chips, which are to climb between 13 percent and 18 percent quarter-on-quarter this quarter, which has not been seen since the fourth quarter of 2021, the Taipei-based market researcher predicted. Likewise, the price of mainstream PC DDR4 DRAM is expected to bounce
SOLID FOUNDATION: Given its decades of expertise in megatronics, manufacturing and robotics, Japan has the wherewithal to create its own AI, Jensen Huang said Nvidia Corp plans to help build an artificial intelligence (AI) tech-related ecosystem in Japan to meet demand in a country eager to gain an edge in this emerging technology. The US company will seek to partner with Japanese research organizations, companies and start-ups to build factories for AI, Nvidia CEO Jensen Huang (黃仁勳) said yesterday during opening remarks in a meeting with Japanese Minister of Economy, Trade and Industry Yasutoshi Nishimura. The company is to set up an AI research laboratory, and invest in local start-ups and educate the public on using AI, Huang said. Huang earlier this week met with Japanese Prime
A Hong Kong court postponed a court hearing on troubled Chinese property developer Evergrande Group’s (恆大集團) winding-up petition scheduled for yesterday until Jan. 29. Evergrande is trying to win support from its creditors for a plan to restructure more than US$300 billion in debt to stave off liquidation. The company’s lawyer told the court it was requesting an adjournment to “refine” its new debt restructuring plan. The Hong Kong High Court has postponed the hearing over Evergrande’s potential liquidation several times. Judge Linda Chan (陳靜芬) had said in October that yesterday’s hearing would be the last before a decision is handed down. Chan
Huawei Technologies Co (華為) is among a field of “very formidable” competitors to Nvidia Corp in the race to produce the best artificial intelligence (AI) chips, Nvidia chief executive officer Jensen Huang (黃仁勳) said yesterday. Huawei, Intel Corp and an expanding group of semiconductor start-ups pose a stiff challenge to Nvidia’s dominant position in the market for AI accelerators, Huang told reporters in Singapore. Shenzhen-based Huawei has grown into China’s chip tech champion and returned to the spotlight this year with an advanced made-in-China smartphone processor. “We have a lot of competitors, in China and outside China,” Huang said. “Most of our competitors